Abstracts tagged "methotrexate (MTX) and rheumatoid arthritis (RA)"

Abstract Number: 2382 • 2019 ACR/ARP Annual Meeting
Relationships Between DAS28 Response and Clinical, Functional and Radiographic Outcomes in Year 2 of the COMET Study of Etanercept in Patients with Rheumatoid Arthritis
Paul Emery¹, Ferdinand Breedveld ², Ronald Pedersen ³, Eduardo Jose Campos ⁴, Annette Szumski ⁵ and Tomohiro Hirose ⁴, ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, United Kingdom, ²Leids Universitair Medisch Centrum, Leiden, Netherlands, ³Pfizer, Collegeville, ⁴Pfizer Japan Inc, Toyko, Japan, ⁵Syneos Health, Princeton, NJ
Background/Purpose: For patients with rheumatoid arthritis (RA) who are treated with etanercept (ETN) plus methotrexate (MTX), dosing down of ETN or withdrawal of MTX are…
Abstract Number: 2383 • 2019 ACR/ARP Annual Meeting
Treatment for Rheumatoid Arthritis After Methotrexate-associated Lymphoproliferative Disorder Developed
Yuji Yoshioka¹, Shouhei Nagaoka ² and Hiroyuki Hagiyama ³, ¹Saiseikai Yokohamashi Nanbu Hospital, Yokohama, Japan, ²Yokohama Minami Kyousai Hospital, Yokohama, Kanagawa, Japan, ³Yokohama City Minato Red Cross Hospital, Yokohama
Background/Purpose: Methotrexate-associated lymphoproliferative disorder (MTX-LPD) is important complication in the rheumatoid arthritis (RA) treatment. There were few reports about clinical features of MTX-LPD and RA…
Abstract Number: L05 • 2018 ACR/ARHP Annual Meeting
Treatment-Naïve, Early Rheumatoid Arthritis Patients Demonstrate Reversible Abnormalities of Vascular Function on Cardiac MRI with RA Therapy with Preliminary Suggestion of Greater Improvement with Anti-TNF Compared to MTX/Conventional Therapy – a First, RCT Derived Longitudinal Study
Maya H. Buch¹, Bara Erhayiem², Graham Fent², Paul Baxter³, Elizabeth M.A. Hensor⁴, Adam McDiarmid², Peter Swoboda⁵, Ananth Kidambi², David Ripley², Pankaj Garg², Sarah Horton⁴, Raluca Bianca Dumitru⁴, Kamran Naraghi⁴, John Greenwood⁶, Paul Emery⁷, Sue Pavitt⁸ and Sven Plein², ¹Leeds Institute of Rheumatic & Musculosekeltal Medicine, University of Leeds & NIHR Biomedical Research Centre, Leeds, United Kingdom, ²Multidisciplinary Cardiovascular Research Centre, Leeds Institute of Cardiovascular & Metabolic Medicine, University of Leeds, Leeds, United Kingdom, ³Leeds Institute of Cardiovascular & Metabolic Medicine, University of Leeds, Leeds, United Kingdom, ⁴Leeds Institute of Rheumatic & Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁵Leeds Institute of Cardiovascular And Metabolic Medicine, University of Leeds, Leeds, United Kingdom, ⁶Leeds Institute of Cardiovascular And Metabolic Medicinee, University of Leeds, Leeds, United Kingdom, ⁷University of Leeds and NIHR Leeds Biomedical Research Centre, Leeds, United Kingdom, ⁸Leeds School of Dentistry, University of Leeds, Leeds, United Kingdom
Background/Purpose: We previously reported abnormal cardiac MRI (CMR)-determined aortic stiffness in patients with early, treatment-naive RA1,2. We now report on whether this vascular stiffness is…
Abstract Number: 1540 • 2018 ACR/ARHP Annual Meeting
Validation of Hepatic Fibrosis Markers in People with Rheumatoid Arthritis on Methotrexate
Debbie Olsson-White¹, John Olynyk^2,3, Warren Raymond^4,5, Shereen Paramalingam^1,5 and Helen Keen^1,6, ¹Rheumatology, Fiona Stanley Hospital, Murdoch, Australia, ²Gastroenterology and Hepatology, Fiona Stanley Hospital, Murdoch, Australia, ³School of Medical and Health Sciences, Edith Cowan University, Joondalup, Australia, ⁴Rheumatology, Sir Charles Gairdner Hospital, Nedlands, Australia, ⁵University of Western Australia, Crawley, Australia, ⁶University of Western Australia, Perth, Australia
Background/Purpose: MTX is the cornerstone of treatment of RA. A relatively rare side effect is liver fibrosis and cirrhosis, the incidence in patients on long-term…
Abstract Number: 2036 • 2018 ACR/ARHP Annual Meeting
Adenosine Receptors Expression As Predictor of Response to Methotrexate Therapy in Patients with Rheumatoid Arthritis
Ankita Singh¹, Ramnath Misra² and Amita Aggarwal², ¹Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, ²Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India
Background/Purpose: Methotrexate (MTX) is first line of therapy to treat Rheumatoid Arthritis (RA) patients and one third of patients do not respond to this drug.…
Abstract Number: 2460 • 2018 ACR/ARHP Annual Meeting
Study of Sixteen Cases of Other Iatrogenic Immunodeficiency-Associated Lymphoproliferative Disorders Developed in Rheumatoid Arthritis Patients
Yoshihiko Ikeno¹, Youkou Kobayashi², Ikuo Akutsu³, Hirokuni Hirata⁴, Masafumi Arima⁵ and Kazuhiro Kurasawa⁶, ¹Rheumatology, Japanese Red Cross Nasu Hospital, Tochigi, Japan, ²Hematology, Japanese Red Cross Nasu Hospital, Tochigi, Japan, ³Respiratory and allergy, Japanese Red Cross Nasu Hospital, Tochigi, Japan, ⁴Respiratory and allergy, Dokkyo Medical University Saitama Medical center, Saitama, Japan, ⁵Rheumatology, Dokkyo Medical University, mibu-gun, Tochigi, Japan, ⁶Rheumatology, Dokkyo Medical University, Mibu, Tochigi, Japan
Background/Purpose: Methotrexate-associated lymphoproliferative disorders (MTX-LPDs) was first reported in 1991. The symptom is known to spontaneously regress after suspending the use of MTX, suggesting its…
Abstract Number: 289 • 2018 ACR/ARHP Annual Meeting
Adherence of Etanercept in Iraqi Patients with Rheumatoid Arthritis: One- and Five-Year Data from a Local Registry
Nizar Abdulateef Al Ani¹, Faiq Isho Gorial¹, Eman Khedir², Ahmed Hussein², Yasser El Dershaby³ and Ali AlJabban⁴, ¹Baghdad Teaching Hospital, College of Medicine, Baghdad University, Baghdad, Iraq, ²Baghdad Teaching Hospital, Rheumatology Department, Baghdad University, Baghdad, Iraq, ³Pfizer, Dubai, United Arab Emirates, ⁴Pfizer, Baghdad, Iraq
Background/Purpose: Real-world data on adherence to TNFα inhibitors in patients with RA are missing from many regions, including the Middle East. This study evaluated the…
Abstract Number: 2814 • 2018 ACR/ARHP Annual Meeting
Methotrexate Use and the Risk for Cardiovascular Disease Among Rheumatoid Patients Initiating Biologic Disease-Modifying Anti-Rheumatic Drugs
Fenglong Xie¹, Lang Chen¹, Emily Levitan², Paul M. Muntner² and Jeffrey R. Curtis¹, ¹University of Alabama at Birmingham, Birmingham, AL, ²Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Methotrexate (MTX) has been associated with reduced risk for cardiovascular disease (CVD) in several studies conducted among rheumatoid arthritis (RA) patients never exposed to…
Abstract Number: 495 • 2018 ACR/ARHP Annual Meeting
Characteristics of Metabolic Syndrome in Men and Women with Early Rheumatoid Arthritis
Bindee Kuriya¹, Orit Schieir², Marie-France Valois³, Janet E. Pope⁴, Gilles Boire⁵, Louis Bessette⁶, Carter Thorne⁷, Diane Tin⁸, Carol A Hitchon⁹, Glen Hazlewood¹⁰, Susan J. Bartlett¹¹, Edward C. Keystone¹², Vivian P. Bykerk¹³ and Lillian Barra¹⁴, ¹Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ²McGill University, Montreal, ON, Canada, ³McGill University, Montreal, QC, Canada, ⁴Department of Medicine, University of Western Ontario, London, ON, Canada, ⁵Rheumatology Division, Centre intégré universitaire de santé et de services sociaux de l'Estrie - Centre Hospitalier Universitaire de Sherbrooke and Universite de Sherbrooke, Sherbrooke, QC, Canada, ⁶Division of Rheumatology, Department of Medicine, CHU de Québec-Université Laval, Québec, QC, Canada, ⁷University of Toronto, Newmarket, ON, Canada, ⁸The Arthritis Program, Southlake Regional Health Centre, Newmarket, ON, Canada, ⁹University of Manitoba, Winnipeg, MB, Canada, ¹⁰Departments of Medicine and Community Health Sciences, University of Calgary, Calgary, AB, Canada, ¹¹Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ¹²Mount Sinai Hospital, Toronto, ON, Canada, ¹³Hospital for Special Surgery, New York, NY, ¹⁴Medicine, Microbiology and Immunology, The University of Western Ontario, London, ON, Canada
Prevalence and Characteristics of Metabolic Syndrome in Men and Women With Early Rheumatoid ArthritisB. Kuriya, O. Schieir, M.F. Valois, J.E. Pope, G. Boire, L. Bessette,…
Abstract Number: 545 • 2018 ACR/ARHP Annual Meeting
How to Treat Rheumatoid Arthritis Patients When Methotrexate Has Failed? Results from the Meteor Registry
Sytske Anne Bergstra¹, Lai-Ling Winchow², Elizabeth Murphy³, Arvind Chopra⁴, Karen Salomon-Escoto⁵, João E. Fonseca⁶, Cornelia F. Allaart¹ and Robert B.M. Landewé⁷, ¹Department of Rheumatology, LUMC, Leiden, Netherlands, ²University of the Witwatersrand, Johannesburg, South Africa, ³University Hospital Wishaw, Scotland, Wishaw, United Kingdom, ⁴Center for Rheumatic Diseases, Pune, India, ⁵University of Massachusetts Medical School, Rheumatology Center, UMass Memorial Medical Center, Worcester, MA, ⁶Serviço de Reumatologia e Doenças Ósseas Metabólicas, Hospital de Santa Maria, CHLN, Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal, ⁷Amsterdam Rheumatology & Immunology Center | Zuyderland Medical Center, Heerlen, Netherlands
Background/Purpose: After failure of initial methotrexate (MTX) treatment in rheumatoid arthritis (RA) patients, various treatment options can be considered. To date, evidence about the preferred…
Abstract Number: 547 • 2018 ACR/ARHP Annual Meeting
Corticosteroid Bridging Strategies with Methotrexate Monotherapy in Early Rheumatoid and Undifferentiated Arthritis; A Comparison of Efficacy and Toxicity in 2 Clinical Trials
Elisabeth G. Brilman¹, Joy A. van der Pol¹, Pascal HP de Jong^2,3, Angelique EAM Weel^2,3, JMW Hazes², Tom W.J. Huizinga⁴ and Cornelia F. Allaart¹, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Rheumatology, Erasmus Medical Center Rotterdam, Rotterdam, Netherlands, ³Rheumatology, Maasstad Hospital, Rotterdam, Netherlands, ⁴Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: What is the optimal glucocorticoid (GC) bridging therapy with MTX monotherapy in early arthritis? Methods: In trial A, early RA and UA (arthritis in ≥1…
Abstract Number: 565 • 2018 ACR/ARHP Annual Meeting
Genetic Polymorphism in Dihydrofolate Reductase Impacts Methotrexate Polyglutamation in Adult Rheumatoid Arthritis
Thierry Dervieux¹, Marie Grosjean², Chuang Jiang^3,4, Kelley Brady¹, Kjeld Schmiegelow², Joel Kremer⁵ and Jun Yang⁴, ¹Exagen Diagnostics, Inc., Vista, CA, ²University Hospital Rigshospitalet, Copenhagen, Denmark, ³Shanghai Children’s Medical Center, Shanghai Jiaotong University School of Medicine, Shanghai, China, ⁴Department of Pharmaceutical Sciences, St. Jude Children’s Research Hospital, Memphis, TN, ⁵Albany Medical College and The Center for Rheumatology, Albany, NY
Background/Purpose: Methotrexate (MTX) is anti-folate activated to MTX polyglutamates (MTXPGs). MTX metabolism includes multiple enzyme-mediated reactions and genetic polymorphisms in these genes are linked to…
Abstract Number: 571 • 2018 ACR/ARHP Annual Meeting
United States Rheumatology Practice-Based Real-World Evidence of Methotrexate Utilization and Response to Therapy in Rheumatoid Arthritis Patients Treated with Intravenous Golimumab
Aaron Broadwell¹, Vance Bray², Douglas Conaway³, Joy Schechtman⁴, Alan J. Kivitz⁵, Dennis Parenti⁶, Shawn Black⁶, Stephen Xu⁷, Wayne Langholff⁷ and Shelly Kafka⁶, ¹Rheumatology Osteoporosis Specialists, Shreveport, LA, ²Denver Arthritis Clinic, Denver, CO, ³Carolina Health Specialists, Myrtle Beach, SC, ⁴Sun Valley Arthritis Center, Peoria, AZ, ⁵Altoona Arthritis & Osteoporosis Center, Altoona, PA, ⁶Janssen Scientific Affairs, LLC, Horsham, PA, ⁷Janssen Research & Development, LLC, Spring House, PA
Background/Purpose: AWARE (Comparative and Pragmatic Study of Golimumab IV Versus Infliximab in Rheumatoid Arthritis) is an ongoing Phase 4 comparator study designed to provide a…
Abstract Number: 598 • 2018 ACR/ARHP Annual Meeting
Real-World Experience of Effectiveness and Safety of Certolizumab Pegol for Rheumatoid Arthritis in Japan: Single-Center Retrospective Study
Naohiro Sugitani^1,2, Eiichi Tanaka¹, Eisuke Inoue^1,3, Eri Sugano¹, Kumiko Saka¹, Moeko Ochiai¹, Rei Yamaguchi¹, Yoko Shimizu¹, Naoki Sugimoto¹, Katsunori Ikari¹, Ayako Nakajima^1,2, Atsuo Taniguchi¹ and Hisashi Yamanaka⁴, ¹Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ²Center for Rheumatic Diseases, Mie University Hospital, Tsu city, Japan, ³Division of Medical Informatics, St. Marianna University School of Medicine, Kawasaki, Japan, ⁴Institute of Rheumatology, Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan
Background/Purpose: Certolizumab-pegol (CZP) is a sixth antitumor necrosis factor inhibitor for rheumatoid arthritis (RA) in Japan. Several clinical trials were conducted to evaluate the efficacy…
Abstract Number: 608 • 2018 ACR/ARHP Annual Meeting
Half Dose Reduction of Methotrexate in Patient with RA Who Achieved Clinical Remission
Takeshi Suzuki, Takayasu Ando, Shoshi Shinagawa, Machiko Mizushima, Tomohiko Shibata and Kimito Kawahata, Division of Rheumatology and Allergology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan
Background/Purpose: Recently, it is recommended that tapering csDMARDs could be considered If a patient is in persistent remission. However, the methods of tapering csDMARDs including…

1
2
3
…
8
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].